BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 21385341)

  • 1. Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer.
    Newnham GM; Conron M; McLachlan S; Dobrovic A; Do H; Li J; Opeskin K; Thompson N; Wright GM; Thomas DM
    BMC Cancer; 2011 Mar; 11():93. PubMed ID: 21385341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
    Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
    J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
    Li B; Cui Y; Diehn M; Li R
    JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
    Bjaanæs MM; Nilsen G; Halvorsen AR; Russnes HG; Solberg S; Jørgensen L; Brustugun OT; Lingjærde OC; Helland Å
    BMC Cancer; 2021 Oct; 21(1):1089. PubMed ID: 34625038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.
    Zhao N; Wilkerson MD; Shah U; Yin X; Wang A; Hayward MC; Roberts P; Lee CB; Parsons AM; Thorne LB; Haithcock BE; Grilley-Olson JE; Stinchcombe TE; Funkhouser WK; Wong KK; Sharpless NE; Hayes DN
    Lung Cancer; 2014 Nov; 86(2):255-61. PubMed ID: 25224251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene copy number aberrations are associated with survival in histologic subgroups of non-small cell lung cancer.
    Micke P; Edlund K; Holmberg L; Kultima HG; Mansouri L; Ekman S; Bergqvist M; Scheibenflug L; Lamberg K; Myrdal G; Berglund A; Andersson A; Lambe M; Nyberg F; Thomas A; Isaksson A; Botling J
    J Thorac Oncol; 2011 Nov; 6(11):1833-40. PubMed ID: 22011649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
    Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
    Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
    Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
    Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
    PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer.
    Tran TN; Selinger CI; Yu B; Ng CC; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
    J Clin Pathol; 2014 Nov; 67(11):985-91. PubMed ID: 25118293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
    Planck M; Isaksson S; Veerla S; Staaf J
    Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer.
    Baty F; Facompré M; Kaiser S; Schumacher M; Pless M; Bubendorf L; Savic S; Marrer E; Budach W; Buess M; Kehren J; Tamm M; Brutsche MH
    Am J Respir Crit Care Med; 2010 Jan; 181(2):181-8. PubMed ID: 19833826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
    Dziadziuszko R; Merrick DT; Witta SE; Mendoza AD; Szostakiewicz B; Szymanowska A; Rzyman W; Dziadziuszko K; Jassem J; Bunn PA; Varella-Garcia M; Hirsch FR
    J Clin Oncol; 2010 May; 28(13):2174-80. PubMed ID: 20351332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
    Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
    J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Wang H; Ou Q; Li D; Qin T; Bao H; Hou X; Wang K; Wang F; Deng Q; Liang J; Zheng W; Wu X; Wang X; Shao YW; Mou Y; Chen L
    Cancer; 2019 Oct; 125(20):3535-3544. PubMed ID: 31287555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients.
    Lu Y; Wang L; Liu P; Yang P; You M
    PLoS One; 2012; 7(1):e30880. PubMed ID: 22292069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
    Peretti U; Ferrara R; Pilotto S; Kinspergher S; Caccese M; Santo A; Brunelli M; Caliò A; Carbognin L; Sperduti I; Garassino M; Chilosi M; Scarpa A; Tortora G; Bria E
    Respir Res; 2016 Aug; 17(1):105. PubMed ID: 27561692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.